Induction of murine syngeneic graft-versus-host disease by cells of recipient origin
- PMID: 17589346
- DOI: 10.1097/01.tp.0000266995.93463.0c
Induction of murine syngeneic graft-versus-host disease by cells of recipient origin
Abstract
Background: Syngeneic graft-versus-host disease (SGVHD) develops after lethal irradiation, reconstitution with syngeneic bone marrow (BM), and treatment with a 21-day course of the immunosuppressant cyclosporine A (CsA). Clinical symptoms of SGVHD appear 2-3 weeks after CsA treatment, with inflammation in the colon and liver. It has been demonstrated that CD4+ T cells and a T helper cell type 1 cytokine response (Th1) are involved in the development of SGVHD associated intestinal inflammation. The immune response associated with SGVHD is thought to be the result of the reconstitution of the recipient immune system with the syngeneic donor BM. However, definitive studies have not addressed this issue experimentally.
Methods: To determine the origin of the effector cells that participate in SGVHD, C3H/HeN recipient mice were lethally irradiated and transplanted with BM from normal immunocompetent mice or from immunodeficient, severe combined immune deficient, or Rag-2-/- animals.
Results: CsA-treated animals, but not control animals, developed inflammation characteristic of SGVHD in the colon and liver regardless of the source of the donor marrow. Furthermore, immunologically, all CsA treated animals responded similarly with increased production of inflammatory cytokines and an increase in activated CD4+ T cells in the periphery and colon relative to controls.
Conclusion: These results demonstrate that after lethal irradiation and in the absence of donor T cells, T cells of recipient origin can expand and mediate the induction of CsA-induced SGVHD.
Similar articles
-
Th1 cytokines and NK cells participate in the development of murine syngeneic graft-versus-host disease.J Immunol. 1999 Aug 1;163(3):1170-7. J Immunol. 1999. PMID: 10415011
-
Murine syngeneic graft-versus-host disease is responsive to broad-spectrum antibiotic therapy.J Immunol. 2011 Mar 15;186(6):3726-34. doi: 10.4049/jimmunol.1003343. Epub 2011 Feb 4. J Immunol. 2011. PMID: 21296982
-
Adoptive transfer of murine syngeneic graft-vs.-host disease by CD4+ T cells.J Leukoc Biol. 2007 Dec;82(6):1393-400. doi: 10.1189/jlb.0307183. Epub 2007 Aug 28. J Leukoc Biol. 2007. PMID: 17726153
-
Syngeneic graft-versus-host disease: a report of two cases and literature review.Bone Marrow Transplant. 2003 Sep;32(5):535-9. doi: 10.1038/sj.bmt.1704171. Bone Marrow Transplant. 2003. PMID: 12942102 Review.
-
Protective conditioning against GVHD and graft rejection after combined organ and hematopoietic cell transplantation.Blood Cells Mol Dis. 2008 Jan-Feb;40(1):48-54. doi: 10.1016/j.bcmd.2007.06.019. Epub 2007 Sep 10. Blood Cells Mol Dis. 2008. PMID: 17827036 Review.
Cited by
-
Accumulation of CD4+ T cells in the colon of CsA-treated mice following myeloablative conditioning and bone marrow transplantation.Am J Physiol Gastrointest Liver Physiol. 2011 May;300(5):G843-52. doi: 10.1152/ajpgi.00254.2010. Epub 2011 Feb 3. Am J Physiol Gastrointest Liver Physiol. 2011. PMID: 21292993 Free PMC article.
-
Long-term skin-resident memory T cells proliferate in situ and are involved in human graft-versus-host disease.Sci Transl Med. 2020 Nov 18;12(570):eabb7028. doi: 10.1126/scitranslmed.abb7028. Sci Transl Med. 2020. PMID: 33208504 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials